Sentinel lymph node biopsy for cutaneous malignant melanoma ; clinical significance

DOI Web Site 10 References
  • TSUDA Tatsuya
    Department of Plastic Surgery, Aizumi Tamaki Aozora Clinic Department of Plastic and Reconstructive Surgery, Tokushima University Graduate School
  • ABE Yoshiro
    Department of Plastic and Reconstructive Surgery, Tokushima University Graduate School
  • ISHIDA Soushi
    Department of Plastic and Reconstructive Surgery, Tokushima University Graduate School
  • MINEDA Kazuhide
    Department of Plastic and Reconstructive Surgery, Tokushima University Graduate School
  • YAMASHITA Yutaro
    Department of Plastic and Reconstructive Surgery, Tokushima University Graduate School
  • NAGASAKA Shinji
    Department of Plastic and Reconstructive Surgery, Tokushima University Graduate School
  • YAMASAKI Yoshiyuki
    Department of Plastic and Reconstructive Surgery, Tokushima University Graduate School
  • KUBO Yoshiaki
    Department of Dermatology, Institute of Biomedical Sciences, Tokushima University Graduate School
  • HASHIMOTO Ichiro
    Department of Plastic and Reconstructive Surgery, Tokushima University Graduate School

Bibliographic Information

Other Title
  • 徳島大学病院で実施された皮膚悪性黒色腫に対するセンチネルリンパ節生検の臨床的意義について

Search this article

Description

<p>Among malignant skin tumors, cutaneous malignant melanoma has poor prognosis, and high risk of metastasis. Sentinel Lymph Node Biopsy (SLNB) is a minimally invasive procedure, for accurate staging and consideration of lymph node dissection. We examined the clinical significance and effect of SLNB, by analyzing 10－year results of treatment, for cutaneous malignant melanoma at Tokushima University Hospital ; SLNB was effective in determining prognosis. Despite lymph node dissection, no effect in improving prognosis was observed. Currently, various molecular－targeted drugs and immune checkpoint inhibitors have appeared as treatments for malignant melanoma, and their therapeutic strategies are still advancing. In the future, clinical trials with adjuvant therapy and SLNB or Complete Lymph Node Dissection, should be conducted to improve prognosis.[Skin Cancer (Japan) 2021 ; 36 : 173－179]</p>

Journal

  • Skin Cancer

    Skin Cancer 36 (2), 173-179, 2021

    The Japanese Skin Cancer Society

References(10)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top